CGH
ATYR

Crossmark Global Holdings’s aTyr Pharma ATYR Stock Holding History

Crossmark Global Holdings’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,666
Closed -$9.88K – 1321
2026
Q1 		$9.88K Hold
12,666
– – ﹤0.01% 1234
2025
Q4 		$9.92K Buy
+12,666
New +$10.4K ﹤0.01% 1224

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crossmark Global Holdings's ATYR Position: Q2 2026 in Review

Crossmark Global Holdings sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 12,666 shares — an estimated $9.88K sold.

Crossmark Global Holdings first reported a position in ATYR in Q4 2025 and held it in 2 quarters. The position peaked at $9.92K in Q4 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Crossmark Global Holdings reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Crossmark Global Holdings sold 12,666 aTyr Pharma shares in Q2 2026, an estimated $9.88K.
  • Crossmark Global Holdings first reported a position in aTyr Pharma in Q4 2025 and held it in 2 quarters.
  • Crossmark Global Holdings's aTyr Pharma position peaked at $9.92K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.